Hep C Treatment - Maxygen achieves milestone payment from Roche

Maxygen achieves milestone payment from Roche
InPharm.com - Maxygen established the alliance with Roche in May 2003, in which Roche licensed worldwide commercialisation rights to specific novel IFN alpha product candidates developed by Maxygen for

Sustained Virologic Response Rates from a Randomized Trial of
HIV and Hepatitis.com - Valeant will pay InterMune $113.5 million in cash upon closing, and subsequent milestone payments of up to approximately $22.5 million. Valeant also will acquire an estimated $6.5 million in inventory from InterMune. that greater than 50% of

Tata Motors rolls out new Novus
Deccan Herald - Tata Motors rolls out new Novus New Delhi,DHNS: Tata Motors, on Wednesday, launched its Tata Novus range of heavy commercial vehicles (

XTL names CEO
TMCnet.com - 6862, developed to prevent hepatitis C, known as

Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and trea
PharmCast - and uses for detecting, preventing and treating an

Novel Drugs From Idenix/Novartis, Vertex, Schering-Plough, and Gilead/Achillion Have Potential to Revolutioniz
PR Newswire - the treatment of the hepatitisC virus (